Articles: pain-measurement.
-
Randomized Controlled Trial
Differential sensitivity of three experimental pain models in detecting the analgesic effects of transdermal fentanyl and buprenorphine.
This is the first randomized controlled trial that tests the analgesic efficacy of transdermally delivered opioids in healthy volunteers and that assesses the sensitivity of different experimental pain tests to detect analgesia in this setting. Transdermal application of the full agonist fentanyl (TDF: 12.5 or 25 microg/h) and the partial agonist buprenorphine (TDB: 35 microg/h) was compared in three experimental models of acute pain (heat pain, painful electrical stimulation, cold pressor) in a double-blind, randomized, placebo-controlled, 4-arm crossover study with 20 healthy subjects (15 men, 5 women). Patches were administered for 72 h and pain levels measured at baseline and 24 and 72 h, with an 11-day wash-out. ⋯ We conclude that the cold pressor test was most sensitive to analgesic effects in healthy subjects and that a transdermal dose of 12.5 microg/h fentanyl achieved significant pain reduction compared with placebo. Subjects experienced opioid-typical AEs including dizziness, nausea and vomiting. No serious AEs occurred.
-
Randomized Controlled Trial Comparative Study
The pain quality assessment scale: assessment of pain quality in carpal tunnel syndrome.
The Neuropathic Pain Scale (NPS) is a valid measure of the pain qualities and perceived depth of neuropathic pain. However, it does not include a number of pain qualities commonly seen in some neuropathic and non-neuropathic pain conditions. To address this limitation, additional items were added to the NPS to create a 20-item measure (Pain Quality Assessment Scale, PQAS) that would be even more useful for assessing neuropathic pain and also would be used to assess pain qualities associated with non-neuropathic pain. To evaluate the responsivity of the PQAS items to pain treatment, secondary analyses were conducted on data from a trial that compared the efficacy of lidocaine patch 5% versus a single steroid injection in 40 patients with carpal tunnel syndrome. Statistically significant (P < .0025) decreases in 10 of the 20 PQAS pain descriptor ratings occurred with both treatments, and 8 ratings showed nonsignificant trends (.0025 < P < .05) for decreasing before treatment to after treatment. No significant differences were found between the 2 treatment conditions on any of the items. The results support the validity of the PQAS items for assessing the effects of pain treatment on pain qualities of carpal tunnel syndrome. ⋯ Clinical trials that include measures of pain qualities can be used to identify the effects of treatments on distinct pain qualities. Measures such as the PQAS can potentially be used to help clinicians target analgesics more efficiently.
-
Osteoarthr. Cartil. · Nov 2006
Randomized Controlled Trial Multicenter StudyAn analgesic model for assessment of acute pain response in osteoarthritis of the knee.
Osteoarthritis (OA) is frequently treated only during periods of flare, in which rapid onset of analgesia is the outcome target. ⋯ This acute pain model of knee OA flare detected significant pain relief with agents known to relieve pain in OA and placebo within hours after the first treatment dose, allowing assessment of pain relief within hours rather than days or weeks when evaluating analgesic efficacy in OA. This model is undergoing further study to determine optimal walk times, distances, and rates to maximize its sensitivity.
-
Randomized Controlled Trial Multicenter Study
Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomized double-blind placebo-controlled multicentre study.
Botulinum type A toxin (BoNT-A) has antinociceptive and muscle-relaxant properties and may help relieve the symptoms of myofascial pain syndrome. In this study we evaluated the efficacy and tolerability of BoNT-A (Dysport) in patients with myofascial pain syndrome of the upper back. We conducted a prospective, randomized, double-blind, placebo-controlled, 12-week, multicentre study. ⋯ Treatment was well tolerated, with most side effects resolving within 8 weeks. In conclusion, in patients with upper back myofascial pain syndrome, injections of 400 Ipsen units of Dysport at 10 individualised trigger points significantly improved pain levels 4-6 weeks after treatment. Injections were well tolerated.
-
Randomized Controlled Trial
Multiple dose gabapentin attenuates cutaneous pain and central sensitisation but not muscle pain in healthy volunteers.
Various muscle pains constitute a large clinical problem, both for patients and clinicians. Gabapentin is an established therapy in neuropathic pain and reduces cutaneous pain in healthy volunteers. Gabapentin in combination with other analgesics reduces post-operative pain. ⋯ Mechanical pain thresholds were unaffected. Pain induced by intramuscular infusion of hypertonic saline was not affected by gabapentin. In conclusion, single or repeated dosing of gabapentin reduced cutaneous but not muscle pain in healthy volunteers.